Loading...

  • regimen
  • A cycle will be one three-week course of the erlotinib-topotecan regimen (the cycle could be extended to 4 weeks if blood studies at 21 days result in treatment delay). (knowcancer.com)
  • clinical trials
  • There can be many years between promising laboratory work and the availability of an effective anti-cancer drug: Monroe Eliot Wall discovered anti-cancer properties in Camptotheca in 1958, but it was not until 1996 - after further research and rounds of clinical trials - that topotecan, a synthetic derivative of a chemical in the plant, was approved for use by the US Food and Drug Administration. (wikipedia.org)
  • Treatment
  • Some unwanted effects may occur after treatment with topotecan has stopped. (drugs.com)
  • RATIONALE: Diagnostic procedures, such as positron emission tomography (PET scan) using 11C topotecan, may help doctors predict a patient's response to treatment and help plan the best treatment. (clinicaltrials.gov)
  • On Day 1 of each treatment cycle, topotecan 0.4 mg/m^2/day will be administered via continuous infusion for 9 days beginning on Day 1 of every 21 day cycle. (knowcancer.com)
  • occur
  • Kidney disease, moderate-Higher blood levels of topotecan can occur, which increases the risk of serious side effects. (mayoclinic.org)
  • Health
  • The investigational agent topotecan may be toxic to the developing fetus or nursing infant and poses unknown health risks. (knowcancer.com)
  • days
  • Subjects received IV weekly Topotecan administered at either 2.5 mg/m2(if the subject had prior pelvic radiotherapy) or 3.0 mg/m2 on Days 1, 8 and 15(+ or - 2 days) every 28 days. (clinicaltrials.gov)